.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,642,538

« Back to Dashboard

Claims for Patent: 8,642,538

Title:Macrocyclic hepatitis C serine protease inhibitors
Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Inventor(s): Ku; Yiyin (Buffalo Grove, IL), McDaniel; Keith F. (Wauconda, IL), Chen; Hui-Ju (Grayslake, IL), Shanley; Jason P. (Chicago, IL), Kempf; Dale J. (Libertyville, IL), Grampovnik; David J. (Waukegan, IL)
Assignee: AbbVie, Inc. (North Chicago, IL)
Application Number:13/439,551
Patent Claims: 1. A compound of formula I or I': ##STR00031## or a pharmaceutically acceptable salt thereof, wherein: J is absent, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, --C(O)--, --O--C(O)--, --N(R.sub.3)--C(O)--, --C(S)--, --C(.dbd.NR.sub.4)--, --S(O)--, --S(O.sub.2)--, or --N(R.sub.3)--; A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic; Each R.sub.1 is independently selected from (i) halogen, hydroxy, amino, --CN, --CF.sub.3, --N.sub.3, --NO.sub.2, --OR.sub.4, --SR.sub.4, --SOR.sub.4, --SO.sub.2R.sub.4, --N(R.sub.3)S(O).sub.2--R.sub.4, --N(R.sub.3)(SO.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4, --C(O)--OR.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or --N(R.sub.3)C(O)R.sub.4; (ii) optionally substituted aryl; (iii) optionally substituted heteroaryl; (iv) optionally substituted heterocyclic; (v) optionally substituted carbocyclic; or (vi) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; G is -E-R.sub.5; wherein E is absent; optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or --O--, --S--, --N(R.sub.3)--, --N(R.sub.3)S(O.sub.p)--, --N(R.sub.3)C(O)--, --N(R.sub.3) C(O)S(O.sub.p)--, --OS(O.sub.p)--, --C(O)S(O.sub.p)--, or --C(O)N(R.sub.3)S(O.sub.p)--; p is 0, 1, or 2; R.sub.5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl; R.sub.3 and R.sub.4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen; L is absent or is selected from optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; j=0, 1, 2, 3, or 4; k=0, 1, 2, or 3; m=0, 1, or 2; n is 0, 1, 2, 3, or 4; and denotes a carbon-carbon single or double bond, Y is --C(R'')--, R' and R'' taken together with the carbon atoms to which they are attached form an aryl or heteroaryl ring, each said ring is optionally substituted.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein k=3, j=1 and L is absent.

3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R.sub.1 is hydrogen or halogen; E is --NHS(O)-- or --NHS(O.sub.2)--, and R.sub.5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted.

4. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein J is --C(O)-- and A is optionally substituted --C.sub.1-C.sub.8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted --C.sub.1-C.sub.8 alkoxy, optionally substituted heteroaryl, optionally substituted --C.sub.3-C.sub.12 cycloalkyl, or optionally substituted --C.sub.3-C.sub.12 heterocycloalkyl.

5. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R' and R'' together form an optionally substituted aryl.

6. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R' and R'', and the atoms to which each is attached, form an aryl which is substituted by (R.sub.2).sub.x, wherein each R.sub.2 is independently selected from (i) halogen, hydroxy, amino, --CN, --CF.sub.3, --N.sub.3, --NO.sub.2, --OR.sub.4, --SR.sub.4, --SOR.sub.4, --SO.sub.2R.sub.4, --NHS(O.sub.2)--R.sub.4, --NHS(O.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4, --C(O)OR.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or --N(R.sub.3)C(O)R.sub.4; (ii) optionally substituted aryl; (iii) optionally substituted heteroaryl; (iv) optionally substituted heterocyclic; (v) optionally substituted carbocyclic; or (iv) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; and x is 0, 1, 2, 3, or 4.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient.

8. A method of treating a hepatitis C viral infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein E is --N(R.sub.3)S(O.sub.p)--, R.sub.3 is H, p is 2, and R.sub.5 is optionally substituted carbocyclic.

10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein R.sub.5 is optionally substituted cyclopropyl.

11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein E is --N(R.sub.3)S(O.sub.p)--, R.sub.3 is H, p is 2, and R.sub.5 is optionally substituted heteroaryl.

12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein J is --C(O)-- and A is optionally substituted heteroaryl.

13. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein A is substituted heteroaryl.

14. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein A is pyrazinyl.

15. The method of claim 8, wherein: k=3; j=1; L is absent; R' and R'', and the atoms to which each is attached, form an aryl which is substituted by (R.sub.2).sub.x; each R.sub.2 is independently selected from (i) halogen, hydroxy, amino, --CN, --CF.sub.3, --N.sub.3, --NO.sub.2, --OR.sub.4, --SR.sub.4, --SOR.sub.4, --SO.sub.2R.sub.4, --NHS(O.sub.2)--R.sub.4, --NHS(O.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4, --C(O)OR.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or --N(R.sub.3)C(O)R.sub.4; (ii) optionally substituted aryl; (iii) optionally substituted heteroaryl; (iv) optionally substituted heterocyclic; (v) optionally substituted carbocyclic; or (iv) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; and x is 0, 1, 2, 3, or 4.

16. The method of claim 8, wherein E is --N(R.sub.3)S(O.sub.p)--, R.sub.3 is H, p is 2, and R.sub.5 is optionally substituted carbocyclic.

17. The method of claim 8, wherein E is --N(R.sub.3)S(O.sub.p)--, R.sub.3 is H, p is 2, and R.sub.5 is optionally substituted heteroaryl.

18. The method of claim 8, wherein J is --C(O)-- and A is optionally substituted heteroaryl.

19. The method of claim 18, wherein A is substituted heteroaryl.

20. The method of claim 18, wherein A is pyrazinyl.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc